{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:15:13Z","timestamp":1788498913674,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL105324"],"award-info":[{"award-number":["T32HL105324"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1R01HL174521-01A1"],"award-info":[{"award-number":["1R01HL174521-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM149404"],"award-info":[{"award-number":["P30GM149404"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>To evaluate the crosstalk between the liver, heart, and kidneys in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), highlighting the distinct regulatory roles of non-traditional hepatokines, and to assess shared therapeutic targets and molecular mechanisms driving cardiorenal complications in MASLD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Emerging evidence highlights that hepatic lipid accumulation drives cardiac damage, which manifests as adverse remodeling, diastolic dysfunction, and coronary microvascular dysfunction. These abnormalities are mediated primarily by systemic lipotoxicity, inflammation of epicardial adipose tissue, and a pro-thrombotic environment. Mechanistically, altered hepatokine signaling mediates systemic cross-talk. Specifically, the downregulation of cardioprotective and renoprotective brain-derived neurotrophic factor (BDNF) and the dual metabolic roles of nerve growth factor (NGF), fibroblast growth factor (FGF) 19, and FGF21 accelerate the progression of both heart failure and chronic kidney disease (CKD). Concurrently, metabolic therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and peroxisome proliferator-activated receptor (PPAR) agonists demonstrate significant efficacy in ameliorating steatosis, inflammation, and overall metabolic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>MASLD acts as a systemic driver of multi-organ dysfunction within the cardio-renal-hepatic axis. Profiling specific hepatokine signatures offers a promising frontier for identifying novel therapeutic targets and biomarkers of disease acceleration. Furthermore, while current metabolic therapies show remarkable potential, rigorous clinical testing remains critical to definitively determine whether their cardiovascular and renal benefits stem from direct tissue-specific protective mechanisms or secondary metabolic improvements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11906-026-01388-1","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:53:25Z","timestamp":1788490405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Cardio-Renal-Hepatic Axis in MASLD. Role of BDNF, NGF, and Metabolic Cross-Talk"],"prefix":"10.1007","volume":"28","author":[{"given":"Lucy C.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"Adenawoola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire B.","family":"Wingfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren K.","family":"Nadolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8359-4008","authenticated-orcid":false,"given":"David E.","family":"Stec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"1","key":"1388_CR1","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","volume":"65","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024;65(1):100485.","journal-title":"J Lipid Res"},{"issue":"9","key":"1388_CR2","doi-asserted-by":"publisher","first-page":"sfaf260","DOI":"10.1093\/ckj\/sfaf260","volume":"18","author":"F Moncho","year":"2025","unstructured":"Moncho F, Benlloch S, Gorriz JL. The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management. Clin Kidney J. 2025;18(9):sfaf260.","journal-title":"Clin Kidney J"},{"key":"1388_CR3","doi-asserted-by":"publisher","first-page":"101557","DOI":"10.1016\/j.lanepe.2025.101557","volume":"62","author":"HT Huang","year":"2026","unstructured":"Huang HT, Hewitt M, Li W, Alazawi W. Real-world evidence in metabolic dysfunction-associated steatotic liver disease (MASLD): insights, challenges, and future directions. Lancet Reg Health Eur. 2026;62:101557.","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"1388_CR4","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1002\/ejhf.70053","volume":"27","author":"Y Huber","year":"2025","unstructured":"Huber Y, Hofmann L, Prochaska JH, Koeck T, Chalabi J, Pfeiffer N, et al. Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population. Eur J Heart Fail. 2025;27(11):2490\u2013500.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"1388_CR5","doi-asserted-by":"publisher","first-page":"e0334720","DOI":"10.1371\/journal.pone.0334720","volume":"20","author":"Y Ono","year":"2025","unstructured":"Ono Y, Sakai K, Okamura T, Okada H, Obora A, Kojima T, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) can be a possible predictive factor of incident CKD: NAGALA cohort study. PLoS ONE. 2025;20(10):e0334720.","journal-title":"PLoS ONE"},{"issue":"2","key":"1388_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","volume":"82","author":"S Driessen","year":"2025","unstructured":"Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatology. 2025;82(2):487\u2013503.","journal-title":"Hepatology"},{"issue":"2","key":"1388_CR7","doi-asserted-by":"publisher","first-page":"113149","DOI":"10.4239\/wjd.v17.i2.113149","volume":"17","author":"MG Suresh","year":"2026","unstructured":"Suresh MG, Mohamed S, Geetha HS, Prabhu S, Trivedi N, Ng ZC, et al. Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: pathophysiology, diagnosis, and emerging therapeutic strategies. World J Diabetes. 2026;17(2):113149.","journal-title":"World J Diabetes"},{"key":"1388_CR8","doi-asserted-by":"publisher","first-page":"120495","DOI":"10.1016\/j.atherosclerosis.2025.120495","volume":"409","author":"C Ratti","year":"2025","unstructured":"Ratti C, Malaguti M, Emanuele D, Bellasi A, Sanna G. Understanding MASLD - from molecular pathogenesis to cardiovascular risk: a concise review for the clinical cardiologist. Atherosclerosis. 2025;409:120495.","journal-title":"Atherosclerosis"},{"key":"1388_CR9","doi-asserted-by":"crossref","unstructured":"Sonaglioni A, Cerini F, Fagiani V, Nicolosi GL, Rumi MG, Lombardo M, et al. Effect of metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) on left ventricular mechanics in patients without overt cardiac disease: a systematic review and meta-analysis. J Clin Med. 2025;14(8).","DOI":"10.3390\/jcm14082690"},{"issue":"1","key":"1388_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-023-01828-1","volume":"22","author":"Y Qu","year":"2023","unstructured":"Qu Y, Liu J, Li J, Shen S, Chen X, Tang H, et al. Association of abdominal adiposity, hepatic shear stiffness with subclinical left-ventricular remodeling evaluated by magnetic resonance in adults free of overt cardiovascular diseases: a prospective study. Cardiovasc Diabetol. 2023;22(1):99.","journal-title":"Cardiovasc Diabetol"},{"key":"1388_CR11","doi-asserted-by":"publisher","first-page":"935390","DOI":"10.3389\/fendo.2022.935390","volume":"13","author":"D Peng","year":"2022","unstructured":"Peng D, Yu Z, Wang M, Shi J, Sun L, Zhang Y, et al. Association of metabolic dysfunction-associated fatty liver disease with left ventricular diastolic function and cardiac morphology. Front Endocrinol (Lausanne). 2022;13:935390.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1388_CR12","first-page":"1777","volume":"41","author":"B Bansal","year":"2025","unstructured":"Bansal B, Lajeunesse-Trempe F, Keshvani N, Lavie CJ, Pandey A. Impact of metabolic dysfunction-associated steatotic liver disease on cardiovascular structure, function, and the risk of heart failure. Can J Cardiol. 2025;41(9):1777\u201393.","journal-title":"Can J Cardiol"},{"key":"1388_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.freeradbiomed.2021.02.016","volume":"167","author":"M Bekhite","year":"2021","unstructured":"Bekhite M, Gonzalez-Delgado A, Hubner S, Haxhikadrija P, Kretzschmar T, Muller T, et al. The role of ceramide accumulation in human induced pluripotent stem cell-derived cardiomyocytes on mitochondrial oxidative stress and mitophagy. Free Radic Biol Med. 2021;167:66\u201380.","journal-title":"Free Radic Biol Med"},{"key":"1388_CR14","doi-asserted-by":"crossref","unstructured":"Mustafa A, Kite C, Lagojda L, Dallaway A, Chatha KK, Than NN, et al. Cardiovascular disease in the context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a comprehensive narrative review. Int J Mol Sci. 2025;26(23).","DOI":"10.3390\/ijms262311275"},{"issue":"3","key":"1388_CR15","doi-asserted-by":"publisher","first-page":"101534","DOI":"10.1016\/j.diabet.2024.101534","volume":"50","author":"G Kim","year":"2024","unstructured":"Kim G, Yu TY, Jee JH, Bae JC, Kang M, Kim JH. Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: a 7-year retrospective cohort study of 3,380 adults using serial echocardiography. Diabetes Metab. 2024;50(3):101534.","journal-title":"Diabetes Metab"},{"key":"1388_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.biocel.2017.05.008","volume":"88","author":"Y Genzer","year":"2017","unstructured":"Genzer Y, Chapnik N, Froy O. Effect of brain-derived neurotrophic factor (BDNF) on hepatocyte metabolism. Int J Biochem Cell Biol. 2017;88:69\u201374.","journal-title":"Int J Biochem Cell Biol"},{"key":"1388_CR17","doi-asserted-by":"crossref","unstructured":"Huning AR, Egypto Rosa VE, Piardi DS, Assis DVR, Ferreira TV, Griseli L, et al. Association between left ventricular global longitudinal strain and hepatic inflammation and fibrosis in metabolic dysfunction-associated steatotic liver disease. Diagnostics (Basel). 2025;15(23).","DOI":"10.3390\/diagnostics15233007"},{"issue":"8","key":"1388_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/oby.21879","volume":"25","author":"TG Simon","year":"2017","unstructured":"Simon TG, Bamira DG, Chung RT, Weiner RB, Corey KE. Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity (Silver Spring). 2017;25(8):1313\u20136.","journal-title":"Obesity (Silver Spring)"},{"key":"1388_CR19","doi-asserted-by":"crossref","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2023;72:372\u2013380","DOI":"10.1136\/gutjnl-2022-327672"},{"issue":"7","key":"1388_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41569-021-00646-w","volume":"19","author":"NG Frangogiannis","year":"2022","unstructured":"Frangogiannis NG. Transforming growth factor-beta in myocardial disease. Nat Rev Cardiol. 2022;19(7):435\u201355.","journal-title":"Nat Rev Cardiol"},{"key":"1388_CR21","doi-asserted-by":"publisher","first-page":"653655","DOI":"10.3389\/fcvm.2021.653655","volume":"8","author":"GB Morrow","year":"2021","unstructured":"Morrow GB, Whyte CS, Mutch NJ. A serpin with a finger in many PAIs: PAI-1\u2019s central function in thromboinflammation and cardiovascular disease. Front Cardiovasc Med. 2021;8:653655.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1388_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1):346.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1388_CR23","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/ehf2.14744","volume":"11","author":"A Schulz","year":"2024","unstructured":"Schulz A, Backhaus SJ, Lange T, Evertz R, Kutty S, Kowallick JT, et al. Impact of epicardial adipose tissue on cardiac function and morphology in patients with diastolic dysfunction. ESC Heart Fail. 2024;11(4):2013\u201322.","journal-title":"ESC Heart Fail"},{"issue":"5","key":"1388_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/NNR.0000000000000454","volume":"69","author":"S Halloway","year":"2020","unstructured":"Halloway S, Jung M, Yeh AY, Liu J, McAdams E, Barley M, et al. An integrative review of brain-derived neurotrophic factor and serious cardiovascular conditions. Nurs Res. 2020;69(5):376\u201390.","journal-title":"Nurs Res"},{"issue":"3","key":"1388_CR25","doi-asserted-by":"publisher","first-page":"e001544","DOI":"10.1161\/JAHA.114.001544","volume":"4","author":"BM Kaess","year":"2015","unstructured":"Kaess BM, Preis SR, Lieb W, Beiser AS, Yang Q, Chen TC, et al. Circulating brain-derived neurotrophic factor concentrations and the risk of cardiovascular disease in the community. J Am Heart Assoc. 2015;4(3):e001544.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"1388_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/cvr\/cvac096","volume":"119","author":"X Yang","year":"2023","unstructured":"Yang X, Zhang M, Xie B, Peng Z, Manning JR, Zimmerman R, et al. Myocardial brain-derived neurotrophic factor regulates cardiac bioenergetics through the transcription factor Yin Yang 1. Cardiovasc Res. 2023;119(2):571\u201386.","journal-title":"Cardiovasc Res"},{"key":"1388_CR27","doi-asserted-by":"publisher","first-page":"1786720","DOI":"10.3389\/fcell.2026.1786720","volume":"14","author":"Y Zhu","year":"2026","unstructured":"Zhu Y, Ran Y, Fu T, Zheng X, Chen Y, Liang C, et al. Cardiomyocyte-derived BDNF restricts cardiac fibrosis by decreasing the activity of the TGF-beta\/Smad2\/3 pathway and increasing Smad7 expression. Front Cell Dev Biol. 2026;14:1786720.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1388_CR28","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1152\/ajpregu.00057.2023","volume":"325","author":"OO Badmus","year":"2023","unstructured":"Badmus OO, Kipp ZA, Bates EA, da Silva AA, Taylor LC, Martinez GJ, et al. Loss of hepatic PPARalpha in mice causes hypertension and cardiovascular disease. Am J Physiol Regul Integr Comp Physiol. 2023;325(1):R81\u201395.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1388_CR29","doi-asserted-by":"crossref","unstructured":"Ichimura-Shimizu M, Kurrey K, Miyata M, Dezawa T, Tsuneyama K, Kojima M. Emerging Insights into the Role of BDNF on Health and Disease in Periphery. Biomolecules. 2024;14(4).","DOI":"10.3390\/biom14040444"},{"issue":"2","key":"1388_CR30","doi-asserted-by":"publisher","first-page":"e0268816","DOI":"10.1371\/journal.pone.0268816","volume":"18","author":"F Moosaie","year":"2023","unstructured":"Moosaie F, Mohammadi S, Saghazadeh A, Dehghani Firouzabadi F, Rezaei N. Brain-derived neurotrophic factor in diabetes mellitus: a systematic review and meta-analysis. PLoS ONE. 2023;18(2):e0268816.","journal-title":"PLoS ONE"},{"issue":"4","key":"1388_CR31","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/hep.30921","volume":"71","author":"J Xiong","year":"2020","unstructured":"Xiong J, Liu T, Mi L, Kuang H, Xiong X, Chen Z, et al. hnRNPU\/TrkB defines a chromatin accessibility checkpoint for liver injury and nonalcoholic steatohepatitis pathogenesis. Hepatology. 2020;71(4):1228\u201346.","journal-title":"Hepatology"},{"issue":"8","key":"1388_CR32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1507\/endocrj.EJ21-0584","volume":"69","author":"Y Hattori","year":"2022","unstructured":"Hattori Y, Yamada H, Munetsuna E, Ando Y, Mizuno G, Fujii R, et al. Increased brain-derived neurotrophic factor in the serum of persons with nonalcoholic fatty liver disease. Endocr J. 2022;69(8):999\u20131006.","journal-title":"Endocr J"},{"key":"1388_CR33","doi-asserted-by":"crossref","unstructured":"Pezzino S, Luca T, Castorina M, Puleo S, Latteri S, Castorina S. Role of perturbated hemostasis in MASLD and its correlation with adipokines. Life (Basel). 2024;14(1).","DOI":"10.3390\/life14010093"},{"issue":"9","key":"1388_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","volume":"19","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593\u2013606.","journal-title":"Nat Rev Cardiol"},{"key":"1388_CR35","doi-asserted-by":"crossref","unstructured":"Konwerski M, Gasecka A, Opolski G, Grabowski M, Mazurek T. Role of epicardial adipose tissue in cardiovascular diseases: a review. Biology (Basel). 2022;11(3).","DOI":"10.3390\/biology11030355"},{"key":"1388_CR36","doi-asserted-by":"publisher","first-page":"932262","DOI":"10.3389\/fcvm.2022.932262","volume":"9","author":"M Conte","year":"2022","unstructured":"Conte M, Petraglia L, Cabaro S, Valerio V, Poggio P, Pilato E, et al. Epicardial adipose tissue and cardiac arrhythmias: focus on atrial fibrillation. Front Cardiovasc Med. 2022;9:932262.","journal-title":"Front Cardiovasc Med"},{"key":"1388_CR37","doi-asserted-by":"crossref","unstructured":"Napoli G, Pergola V, Basile P, De Feo D, Bertrandino F, Baggiano A, et al. Epicardial and pericoronary adipose tissue, coronary inflammation, and acute coronary syndromes. J Clin Med. 2023;12(23).","DOI":"10.3390\/jcm12237212"},{"issue":"6","key":"1388_CR38","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/met.2011.0024","volume":"9","author":"HS Sacks","year":"2011","unstructured":"Sacks HS, Fain JN, Cheema P, Bahouth SW, Garrett E, Wolf RY, et al. Depot-specific overexpression of proinflammatory, redox, endothelial cell, and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis. Metab Syndr Relat Disord. 2011;9(6):433\u20139.","journal-title":"Metab Syndr Relat Disord"},{"issue":"20","key":"1388_CR39","doi-asserted-by":"publisher","first-page":"10747","DOI":"10.1074\/jbc.M116.722272","volume":"291","author":"DD Pham","year":"2016","unstructured":"Pham DD, Do HT, Bruelle C, Kukkonen JP, Eriksson O, Mogollon I, et al. p75 neurotrophin receptor signaling activates sterol regulatory element-binding protein-2 in hepatocyte cells via p38 mitogen-activated protein kinase and caspase-3. J Biol Chem. 2016;291(20):10747\u201358.","journal-title":"J Biol Chem"},{"issue":"7","key":"1388_CR40","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1161\/CIRCRESAHA.109.210088","volume":"106","author":"M Meloni","year":"2010","unstructured":"Meloni M, Caporali A, Graiani G, Lagrasta C, Katare R, Van Linthout S, et al. Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res. 2010;106(7):1275\u201384.","journal-title":"Circ Res"},{"key":"1388_CR41","doi-asserted-by":"crossref","unstructured":"Yu T. Neurocardiac Crosstalk: Sympathetic remodeling and arrhythmogenesis after myocardial infarction. Curr Issues Mol Biol. 2025;47(12).","DOI":"10.3390\/cimb47121037"},{"issue":"1","key":"1388_CR42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12933-023-02070-5","volume":"22","author":"TG Simon","year":"2023","unstructured":"Simon TG, Ebrahimi F, Roelstraete B, Hagstrom H, Sundstrom J, Ludvigsson JF. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study. Cardiovasc Diabetol. 2023;22(1):343.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1388_CR43","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/joim.12964","volume":"286","author":"H Park","year":"2019","unstructured":"Park H, Dawwas GK, Liu X, Nguyen MH. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. J Intern Med. 2019;286(6):711\u201322.","journal-title":"J Intern Med"},{"key":"1388_CR44","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.freeradbiomed.2024.09.011","volume":"224","author":"S Lu","year":"2024","unstructured":"Lu S, Jin H, Nong T, Li D, Long K, Chen Y, et al. Hepatocyte-derived Fetuin-A promotes alcohol-associated liver disease in mice by inhibiting autophagy-lysosome degradation of TLR and M2 macrophage polarization. Free Radic Biol Med. 2024;224:506\u201320.","journal-title":"Free Radic Biol Med"},{"key":"1388_CR45","doi-asserted-by":"crossref","unstructured":"Milani I, Codini M, Guarisco G, Chinucci M, Gaita C, Leonetti F, et al. Hepatokines and MASLD: the GLP1-Ras-FGF21-fetuin-a crosstalk as a therapeutic target. Int J Mol Sci. 2024;25(19).","DOI":"10.3390\/ijms251910795"},{"issue":"6","key":"1388_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","volume":"16","author":"V Vallon","year":"2020","unstructured":"Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16(6):317\u201336.","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"1388_CR47","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4093\/dmj.2021.0130","volume":"46","author":"DH Seo","year":"2022","unstructured":"Seo DH, Suh YJ, Cho Y, Ahn SH, Seo S, Hong S, et al. Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Diabetes Metab J. 2022;46(4):630\u20139.","journal-title":"Diabetes Metab J"},{"issue":"8","key":"1388_CR48","doi-asserted-by":"publisher","first-page":"e104941","DOI":"10.1371\/journal.pone.0104941","volume":"9","author":"G Sesti","year":"2014","unstructured":"Sesti G, Sciacqua A, Fiorentino TV, Perticone M, Succurro E, Perticone F. Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. PLoS ONE. 2014;9(8):e104941.","journal-title":"PLoS ONE"},{"issue":"12","key":"1388_CR49","doi-asserted-by":"publisher","first-page":"114143","DOI":"10.1016\/j.isci.2025.114143","volume":"28","author":"L Gonzalez-Rodriguez","year":"2025","unstructured":"Gonzalez-Rodriguez L, Marti-Antonio M, Mota-Zamorano S, Chicharro C, Cancho B, Alvarez A, et al. Combined concentrations and genetic variability of fibroblast growth factors predict cardiovascular risk in renal patients. iScience. 2025;28(12):114143.","journal-title":"iScience"},{"key":"1388_CR50","doi-asserted-by":"publisher","first-page":"155616","DOI":"10.1016\/j.metabol.2023.155616","volume":"145","author":"A Giontella","year":"2023","unstructured":"Giontella A, Zagkos L, Geybels M, Larsson SC, Tzoulaki I, Mantzoros CS, et al. Renoprotective effects of genetically proxied fibroblast growth factor 21: mendelian randomization, proteome-wide and metabolome-wide association study. Metabolism. 2023;145:155616.","journal-title":"Metabolism"},{"issue":"6","key":"1388_CR51","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1016\/j.clnu.2021.01.036","volume":"40","author":"A Post","year":"2021","unstructured":"Post A, Groothof D, Schutten JC, Kelly D, Swarte JC, Flores-Guerrero JL, et al. Fibroblast growth factor 21 and protein energy wasting in hemodialysis patients. Clin Nutr. 2021;40(6):4216\u201324.","journal-title":"Clin Nutr"},{"key":"1388_CR52","doi-asserted-by":"crossref","unstructured":"Bartmanska M, Wiecek A, Adamczak M. Plasma FGF21 concentration in kidney transplant patients-results from prospective and cross-sectional studies. J Clin Med. 2024;13(14).","DOI":"10.3390\/jcm13144266"},{"issue":"5","key":"1388_CR53","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1159\/000502647","volume":"44","author":"M Marchelek-Mysliwiec","year":"2019","unstructured":"Marchelek-Mysliwiec M, Dziedziejko V, Nowosiad-Magda M, Dolegowska K, Dolegowska B, Pawlik A, et al. Chronic kidney disease is associated with increased plasma levels of fibroblast growth factors 19 and 21. Kidney Blood Press Res. 2019;44(5):1207\u201318.","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"1388_CR54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/15548627.2023.2259282","volume":"20","author":"S Minami","year":"2024","unstructured":"Minami S, Sakai S, Yamamoto T, Takabatake Y, Namba-Hamano T, Takahashi A, et al. FGF21 and autophagy coordinately counteract kidney disease progression during aging and obesity. Autophagy. 2024;20(3):489\u2013504.","journal-title":"Autophagy"},{"key":"1388_CR55","doi-asserted-by":"crossref","unstructured":"Jee YM, Lee JY, Ryu T. Chronic inflammation and immune dysregulation in metabolic-dysfunction-associated steatotic liver disease progression: from steatosis to hepatocellular carcinoma. Biomedicines. 2025;13(5).","DOI":"10.3390\/biomedicines13051260"},{"issue":"9","key":"1388_CR56","doi-asserted-by":"publisher","first-page":"118295","DOI":"10.12998\/wjcc.v14.i9.118295","volume":"14","author":"H-Y Pan","year":"2026","unstructured":"Pan H-Y, Liang J-X, Chen W-W, Sheng Y-Y, Zhang W-J, Zhu X-W, et al. Beyond glycemic control: how semaglutide reshapes intestinal neuroception via transforming growth factor-\u03b2\/brain-derived neurotrophic factor signaling hubs. World J Clin Cases. 2026;14(9):118295.","journal-title":"World J Clin Cases"},{"issue":"5","key":"1388_CR57","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.7150\/thno.126199","volume":"16","author":"A Belmer","year":"2026","unstructured":"Belmer A, Luci C, Gual P. Role of central and peripheral serotonin in liver physiology and diseases. Theranostics. 2026;16(5):2284\u2013309.","journal-title":"Theranostics"},{"key":"1388_CR58","doi-asserted-by":"crossref","unstructured":"Beknazarova A, Kuvaeva V, Baltin M, Mutig K, Bobylev A. BDNF\/TrkB signaling in the brain-kidney axis under functional stress. Biology (Basel). 2026;15(9).","DOI":"10.3390\/biology15090696"},{"issue":"22","key":"1388_CR59","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1007\/s00018-014-1628-x","volume":"71","author":"K Varendi","year":"2014","unstructured":"Varendi K, Kumar A, Harma MA, Andressoo JO. MiR-1, miR-10b, miR-155, and miR-191 are novel regulators of BDNF. Cell Mol Life Sci. 2014;71(22):4443\u201356.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"1388_CR60","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/jdi.13690","volume":"13","author":"BC Mkhize","year":"2022","unstructured":"Mkhize BC, Mosili P, Ngubane PS, Sibiya NH, Khathi A. Diet-induced prediabetes: effects on the activity of the renin-angiotensin-aldosterone system in selected organs. J Diabetes Investig. 2022;13(5):768\u201380.","journal-title":"J Diabetes Investig"},{"issue":"10","key":"1388_CR61","doi-asserted-by":"publisher","first-page":"114860","DOI":"10.1016\/j.celrep.2024.114860","volume":"43","author":"PY N\u2019Guetta","year":"2024","unstructured":"N\u2019Guetta PY, McLarnon SR, Tassou A, Geron M, Shirvan S, Hill RZ, et al. Comprehensive mapping of sensory and sympathetic innervation of the developing kidney. Cell Rep. 2024;43(10):114860.","journal-title":"Cell Rep"},{"key":"1388_CR62","doi-asserted-by":"crossref","unstructured":"Samario-Roman J, Larque C, Panico P, Ortiz-Huidobro RI, Velasco M, Escalona R, et al. NGF and its role in immunoendocrine communication during metabolic syndrome. Int J Mol Sci. 2023;24(3).","DOI":"10.3390\/ijms24031957"},{"issue":"3","key":"1388_CR63","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.devcel.2016.10.003","volume":"39","author":"J Houtz","year":"2016","unstructured":"Houtz J, Borden P, Ceasrine A, Minichiello L, Kuruvilla R. Neurotrophin signaling is required for glucose-induced insulin secretion. Dev Cell. 2016;39(3):329\u201345.","journal-title":"Dev Cell"},{"key":"1388_CR64","doi-asserted-by":"crossref","unstructured":"Minnone G, De Benedetti F, Bracci-Laudiero L. NGF and Its receptors in the regulation of inflammatory response. Int J Mol Sci. 2017;18(5).","DOI":"10.3390\/ijms18051028"},{"key":"1388_CR65","doi-asserted-by":"publisher","first-page":"127694","DOI":"10.1016\/j.jtemb.2025.127694","volume":"90","author":"M Usta","year":"2025","unstructured":"Usta M, Cigremis Y, Ozen H. Nerve growth factor acts as a modulator on the p38 MAPK pathway in copper-induced liver damage. J Trace Elem Med Biol. 2025;90:127694.","journal-title":"J Trace Elem Med Biol"},{"issue":"7","key":"1388_CR66","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41419-019-1758-z","volume":"10","author":"DD Pham","year":"2019","unstructured":"Pham DD, Bruelle C, Thi Do H, Pajanoja C, Jin C, Srinivasan V, et al. Caspase-2 and p75 neurotrophin receptor (p75NTR) are involved in the regulation of SREBP and lipid genes in hepatocyte cells. Cell Death Dis. 2019;10(7):537.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1388_CR67","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/hep.22701","volume":"49","author":"TJ Kendall","year":"2009","unstructured":"Kendall TJ, Hennedige S, Aucott RL, Hartland SN, Vernon MA, Benyon RC, et al. P75 neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. Hepatology. 2009;49(3):901\u201310.","journal-title":"Hepatology"},{"issue":"3","key":"1388_CR68","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/08977194.2015.1054989","volume":"33","author":"D Vizza","year":"2015","unstructured":"Vizza D, Perri A, Toteda G, Lupinacci S, Leone F, Gigliotti P, et al. Nerve growth factor exposure promotes tubular epithelial-mesenchymal transition via TGF-beta1 signaling activation. Growth Factors. 2015;33(3):169\u201380.","journal-title":"Growth Factors"},{"key":"1388_CR69","doi-asserted-by":"crossref","unstructured":"Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, et al. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int J Mol Sci. 2023;24(2).","DOI":"10.3390\/ijms24021703"},{"issue":"1","key":"1388_CR70","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1038\/s41598-025-89408-z","volume":"15","author":"B Havranek","year":"2025","unstructured":"Havranek B, Loh R, Torre B, Redfield R, Halegoua-DeMarzio D. Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes. Sci Rep. 2025;15(1):4947.","journal-title":"Sci Rep"},{"key":"1388_CR71","doi-asserted-by":"crossref","unstructured":"Tornea DA, Goldis C, Isaic A, Motofelea AC, Sima AC, Ciocarlie T, et al. The effect of GLP-1 agonists on patients with metabolic-associated steatotic liver disease: a systematic review and meta-analysis. Pharmaceutics. 2026;18(1).","DOI":"10.3390\/pharmaceutics18010086"},{"issue":"12","key":"1388_CR72","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324.","journal-title":"N Engl J Med"},{"issue":"24","key":"1388_CR73","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"1388_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1388_CR75","doi-asserted-by":"publisher","first-page":"1667823","DOI":"10.3389\/fmed.2025.1667823","volume":"12","author":"L Yang","year":"2025","unstructured":"Yang L, Ruan J, Fang Y, Xu A. Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs. Front Med (Lausanne). 2025;12:1667823.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"1388_CR76","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/dom.16198","volume":"27","author":"K Hirayama","year":"2025","unstructured":"Hirayama K, Koshizaka M, Ishibashi R, Shoji M, Horikoshi T, Sakurai K, et al. Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: sub-analysis of a randomized controlled study. Diabetes Obes Metab. 2025;27(4):2059\u201369.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1388_CR77","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.17305\/bb.2025.12203","volume":"25","author":"Q Ge","year":"2025","unstructured":"Ge Q, Zhang F, Liu Y. Effect of SGLT2 inhibitors on liver fat content: a meta-analysis. Biomolecules Biomed. 2025;25(12):2647\u201357.","journal-title":"Biomolecules Biomed"},{"key":"1388_CR78","doi-asserted-by":"crossref","unstructured":"Rastogi A, Januzzi JL Jr. Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors in cardiovascular disease and chronic kidney disease. J Clin Med. 2023;12(8).","DOI":"10.3390\/jcm12082824"},{"issue":"2","key":"1388_CR79","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1388_CR80","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2337\/dsi23-0012","volume":"37","author":"I Genua","year":"2024","unstructured":"Genua I, Cusi K. Pharmacological approaches to nonalcoholic fatty liver disease: current and future therapies. Diabetes Spectr. 2024;37(1):48\u201358.","journal-title":"Diabetes Spectr"},{"key":"1388_CR81","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.clinsp.2025.100737","volume":"80","author":"IVA Pereira","year":"2025","unstructured":"Pereira IVA, de Oliveira ABS, Zitelli PMY, Barbieri LA, Cardoso AC, Monteiro M, et al. Long-term pioglitazone use in MASLD patients: insights from a multicentric preliminary study. Clinics (Sao Paulo). 2025;80:100737.","journal-title":"Clinics (Sao Paulo)"},{"issue":"11","key":"1388_CR82","doi-asserted-by":"publisher","first-page":"17","DOI":"10.59556\/japi.73.1250","volume":"73","author":"V Panikar","year":"2025","unstructured":"Panikar V, Gupta A, Nasikkar N, Joshi S, Walwalkar S, Sachdev I, et al. Evaluating pioglitazone for managing type 2 diabetes mellitus in patients with nonalcoholic fatty liver disease. J Assoc Physicians India. 2025;73(11):17\u20139.","journal-title":"J Assoc Physicians India"},{"issue":"1","key":"1388_CR83","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12916-025-04017-x","volume":"23","author":"M Lee","year":"2025","unstructured":"Lee M, Hong S, Cho Y, Rhee H, Yu MH, Bae J, et al. Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial. BMC Med. 2025;23(1):266.","journal-title":"BMC Med"},{"issue":"4","key":"1388_CR84","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/hep.31843","volume":"74","author":"S Gawrieh","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, et al. Saroglitazar, a PPAR-alpha\/gamma agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology. 2021;74(4):1809\u201324.","journal-title":"Hepatology"},{"issue":"4","key":"1388_CR85","doi-asserted-by":"publisher","first-page":"e70558","DOI":"10.1111\/liv.70558","volume":"46","author":"A Sanyal","year":"2026","unstructured":"Sanyal A, Doshi S, Behl N, Gupta HK, Bhatia V, Kavitha A, et al. Saroglitazar 4 Mg in metabolic dysfunction-associated steatotic liver disease: 24-week results from phase 4 study. Liver Int. 2026;46(4):e70558.","journal-title":"Liver Int"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-026-01388-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:26Z","timestamp":1788495866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-026-01388-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1388"],"URL":"https:\/\/doi.org\/10.1007\/s11906-026-01388-1","relation":{},"ISSN":["1534-3111"],"issn-type":[{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}],"article-number":"36"}}